Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: A systematic literature review based on 222 cases

Imagem de Miniatura




Denadai, Rafael [UNESP]
Teixeira, Fábio Vieira [UNESP]
Steinwurz, Flavio
Romiti, Ricardo
Saad-Hossne, Rogério [UNESP]

Título da Revista

ISSN da Revista

Título de Volume



Background: Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti-TNF therapy. Methods: Published studies were identified by a search of Medline, Embase, Cochrane, SciELO, and LILACS databases. Results: A total of 47 studies (222 patients) fulfilled the inclusion criteria and were selected for analysis. Clinical and therapeutic aspects varied considerably among these reports. Of the 222 patients, 78.38% were diagnosed with Crohn's disease, and 48.20% were female. The mean patient age was 26.50. years, and 70.72% of patients had no history of psoriasis. Patients developed psoriasiform lesions (55.86%) more often than other types of psoriatic lesions, and infliximab was the anti-TNF-α therapy that caused the cutaneous reaction in most patients (69.37%). Complete remission of cutaneous lesions was observed in 63.96% of the cases. Conclusions: We found that psoriatic lesions occurred predominantly in adult patients with Crohn's disease who received infliximab and had no previous history of psoriasis. Most patients can be managed conservatively without discontinuing anti-TNF-α therapy. © 2012 European Crohn's and Colitis Organisation.



Adalimumab;, Biological therapy, Certolizumab;, Inflammatory bowel disease;, Infliximab;, Psoriasis;, adalimumab, azathioprine, certolizumab pegol, corticosteroid, etanercept, infliximab, mesalazine, methotrexate, tumor necrosis factor alpha inhibitor, Crohn disease, drug withdrawal, enteritis, human, priority journal, psoriasis, pustulosis palmoplantaris, review, skin manifestation, spondylarthritis, systematic review

Como citar

Journal of Crohn's and Colitis, v. 7, n. 7, p. 517-524, 2013.